The new dedicated research center in Gydnia will have the capacity for four full-time investigators, with an increase from one hundred to three hundred square metres of space and will include a wide range of diagnostic instruments to cover Synexus’ expanding therapy area coverage.
Synexus has been operating in Poland since 2006 from its site in Wroclaw and expanded its operations there in August 2009 when it acquired three new dedicated research centers in Warsaw, Gdynia and Katowice, following its takeover of CLCC.
Michael Fort, CEO of the company, said: "We are continuing to see increased levels of interest for clinical trials throughout the CEE, not least in Poland where our sites are very well located and staffed by highly qualified and experienced professionals. The pharma companies and CROs we are talking to continue to express their enthusiasm for increased capacity across the CEE and we are keen to help meet their demands."
Will Synexus benefit with the expansion?
Have your say and discuss with your peers on the Info Grok community.
Participate by posting your comments now.